Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][19]. Core Insights - The company, as the largest e-commerce SaaS ERP provider in China, has established a broad ecosystem through its products and services, with steady revenue and profit growth. The integration of AI into e-commerce ERP opens up new application scenarios [2][10]. - The company is expected to achieve revenue of 11.33 billion, 14.02 billion, and 17.06 billion RMB from 2025 to 2027, with year-on-year growth rates of 24.55%, 23.69%, and 21.73% respectively. The net profit attributable to the parent company is projected to be 1.80 billion, 3.60 billion, and 5.57 billion RMB, with EPS of 0.41, 0.82, and 1.28 RMB [10][12]. Financial Summary - The company’s total revenue is forecasted to grow from 6.97 billion RMB in 2024 to 17.06 billion RMB in 2027, with a compound annual growth rate (CAGR) of 21.73% [4][12]. - Gross profit is expected to increase from 623 million RMB in 2024 to 1.37 billion RMB in 2027, indicating a rising gross margin from 62.3% to 80.37% [4][12]. - The company’s net profit is projected to turn positive in 2024, reaching 12 million RMB, and further increasing to 557 million RMB by 2027 [4][12]. Market Position and Strategy - The company aims to address the pain points of e-commerce merchants operating across multiple platforms and stores, focusing on order, inventory, logistics, and finance management [13]. - The e-commerce SaaS market in China is expected to grow from 73 billion RMB in 2020 to 129 billion RMB in 2024, with a CAGR of 15.4%. The e-commerce SaaS ERP market is projected to grow from 16 billion RMB to 31 billion RMB in the same period, with a CAGR of 18.9% [13]. - The company is actively expanding its overseas business, implementing a "one body, two wings" strategy to stabilize its domestic market while pursuing cross-border and international growth opportunities [13]. Valuation - The report employs both PS and PE valuation methods, with a target price set at 28.56 HKD based on a cautious approach to the lower end of the valuation range [15][19]. - The PS valuation method suggests a reasonable market value of 124.58 billion HKD, while the PE valuation method indicates a market value of 131.94 billion HKD, leading to a target price of 30.24 HKD [17][19].

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of 105.54 HKD for the next six months [5][3]. Core Insights - The company is positioned as a leader in the AI medical sector, leveraging strong AI capabilities to maintain a high market share while actively entering new markets. The AI healthcare solutions market is projected to exceed 20 billion CNY by 2025 and 100 billion CNY by 2030, with a CAGR of 43.2% [1][3][36]. - The company has developed a comprehensive service model covering grassroots medical institutions, hospitals, and patients, supported by national policies that drive the AI medical industry [1][2][36]. - The company is expected to continue refining its core capabilities in AI medical models and expand its service offerings to patients, creating new revenue streams [3][2]. Summary by Sections 1. AI Medical Leader, Policy and Technology Driving Growth - The company is recognized as a leader in the AI medical field, providing a full range of services across grassroots medical institutions, hospitals, and patients [16][1]. - The company has achieved significant revenue growth, with a projected increase from 9.25 billion CNY in 2025 to 15.77 billion CNY in 2027, while narrowing net losses [9][3]. 2. Building Proprietary Large Models, Creating a Comprehensive AI Medical Technology System - The company has developed the "Spark Medical Model," which ranks first in MedBench evaluations and has clinical capabilities equivalent to attending physicians [1][2]. - Continuous upgrades to the AI model and collaboration with top hospitals enhance the reliability and commercial replicability of its technology [1][2]. 3. Policy-Driven Development of G-End, Constructing a Comprehensive Smart Medical System - The company has established a strong presence in 31 provinces and over 77,000 grassroots medical institutions, providing over 1.1 billion AI-assisted diagnostic suggestions [2][1]. - The company’s smart hospital solutions cover pre-diagnosis, diagnosis, and post-diagnosis stages, enhancing patient management and hospital service efficiency [2][1]. 4. Accelerating B-End Smart Hospital Construction, AI Empowering Competitive Advantages - The company is rapidly expanding its smart hospital framework, establishing a solid foundation for B-end business development [2][1]. - The dual focus on smart hospitals and AI assistants is driving the intelligent transformation of hospital services [2][1]. 5. Extending C-End Patient Services, Accelerating AI-Enabled Health Management Layout - The company is actively developing AI products for patients, enhancing personalized health management and follow-up services [2][1]. - The integration of AI in patient management is expected to create a closed-loop service model from doctors to patients, driving new growth [2][1]. 6. Profit Forecast and Investment Recommendations - The company is projected to achieve revenues of 9.25 billion CNY in 2025, 12.56 billion CNY in 2026, and 15.77 billion CNY in 2027, with a gradual improvement in profitability [9][3]. - The report emphasizes the potential for significant growth driven by policy support and technological advancements in the AI medical sector [3][1].

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (00388.HK) [2][7] Core Insights - The company achieved record high performance in 2025, with total revenue and other income reaching HKD 29.161 billion, a year-on-year increase of 30% [5] - Shareholder profit attributable to the company was HKD 17.700 billion, up 36% year-on-year, driven by a 32% increase in main business revenue due to a surge in trading volume [5] - The IPO market saw a significant rebound, with 119 new listings raising a total of HKD 286.9 billion, a 226% increase year-on-year, reclaiming the top position globally for IPO fundraising [5] Financial Performance - In 2025, the average daily trading volume (ADT) for Hong Kong stocks reached HKD 2,498 billion, a remarkable 89.5% increase year-on-year, with southbound funds becoming a crucial liquidity source [5][6] - The derivatives market also showed strong performance, with an average daily contract volume of 1.66 million, a 7% increase year-on-year, and stock options being a particularly active segment with a 22% increase [5] - The company’s strategic initiatives included diversifying asset classes and enhancing global connectivity, with significant progress in fixed income and currency businesses [5][6] Earnings Forecast - Projected revenues for 2025, 2026, and 2027 are HKD 31.960 billion, HKD 34.331 billion, and HKD 37.597 billion respectively, with growth rates of 9.60%, 7.42%, and 9.51% [7][8] - Expected net profits for the same years are HKD 20.463 billion, HKD 22.043 billion, and HKD 24.357 billion, reflecting growth rates of 15.61%, 7.72%, and 10.50% [7][8] - The report indicates a price-to-earnings (P/E) ratio of 25.40 for 2026, decreasing to 21.34 by 2028 [7][8]

里昂证券 江南布衣(03306):升目标价至25港元,评级"跑赢大市" 里昂发布研报称，江南布衣(21.94,0.42,1.95%)(03306)目标价由17港元上调至25港元，其评级为"跑赢 大市"。上周五(2月27日)股价上升7%，受惠于去年12月底止2026财年上半年净利润胜于预期，以及稳健迈向 2026财年销售及净利润目标(分别60亿及9亿元人民币)。毛利率扩大1.4个百分点，受惠折扣控制得当，以及利 好品牌和渠道组合。 该行预料，集团2026财年销售和净利润同比升9%和13%，同时将2026年至2027年销售及净利润预测分别上 调0%及2%至3%，上调估值基础，对未来12个月市盈率目标由8倍上调至10倍。 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company, Lao Pu Gold (06181), has increased prices by 20% to 30% since the end of February, with the average increase slightly above market expectations, particularly for pure gold products [1] - This price adjustment is expected to help protect the company's gross margin, as management aims for a gross margin of 40% by 2026, especially since the company's pricing had lagged behind gold price increases prior to the October price hike [1] - The company had pre-stocked inventory in October to prepare for the peak season, which is anticipated to mitigate the risk of declining gross margins during the January to February peak season [1] - Despite market concerns regarding sustainability of growth post-price increase and after the Lunar New Year promotional period, strong performance during January and February is expected to support a solid growth outlook for the first half of the year [1] - The brand upgrade cycle remains robust, which is expected to support performance in the context of rising gold prices [1]

Investment Rating - The report maintains an "Overweight" rating for HSBC Holdings with a target price of HKD 165 [1] Core Insights - HSBC's Q4 2025 performance and mid-term tangible return on equity (ROTE) guidance exceeded expectations [1] - The earnings briefing conveyed positive messages, with management clearly outlining revenue growth trajectories from 2026 to 2028, drivers of net interest income growth, and a roadmap for achieving business synergies [1] - Management's explanation regarding costs alleviates market concerns about insufficient investments in key areas such as technology and artificial intelligence [1] - A strong currency is anticipated to persist, with the next catalyst being the investor day scheduled for May [1]

Investment Rating - The report assigns a "Buy" rating to Samsonite (01910) with a target price of HKD 24.8 [1] Core Insights - The report anticipates that the recent U.S. Supreme Court ruling on the legality of tariffs and subsequent adjustments will effectively reduce the tariff rate faced by Samsonite to a low single-digit percentage within the next five months [1] - It is expected that Samsonite's U.S. wholesale customers will take advantage of this window period to replenish inventory, which will drive revenue recovery in the U.S. market amid strong travel demand [1] - Concerns regarding a potential 15% discount on the issuance price and related share dilution have contributed to the stock's weakness since mid-February, overshadowing the potential for a valuation reassessment in line with global peers following the U.S. listing [1] - Positive indicators have been observed from the performance of global airlines, online travel agencies, hotels, and luxury goods companies, suggesting a favorable revenue trend for Samsonite [1] - Over the past seven quarters, Samsonite's revenue trend has shown a high correlation with LVMH [1]

Investment Rating - The report maintains a "Buy" rating for Tencent Holdings with a target price of HKD 780 [1] Core Insights - Tencent's stock has declined approximately 13% year-to-date, underperforming the Hang Seng Tech Index and the Hang Seng Index, primarily due to investor concerns regarding potential industry disruption from AI and Tencent's competitive position in the AI space [1] - Despite the stock's decline, UBS believes that most downside risks are already reflected in the stock price and highlights positive developments in Tencent's AI and gaming businesses that investors may be overlooking [1] - The report emphasizes that success in the AI sector hinges on the ability to integrate high-quality models, a strong user base, and extensive data, noting that WeChat's 1.4 billion users and its diverse application scenarios provide Tencent with unique advantages that are difficult to replicate [1]

Group 1 - The investment rating for Galaxy Entertainment is maintained at "Overweight" with a target price of HKD 52 [1] - The core performance highlights include a quarterly market share increase of 160 basis points to 21.7% and a quarterly profit expansion of 29% [1] - The final dividend of HKD 0.8 per share indicates a payout ratio of 61% for the fiscal year 2025, which is considered a solid performance but may disappoint some investors seeking higher dividends [1] Group 2 - The report did not identify any particularly negative factors in the earnings results [1] - There is an expectation that future dividends will gradually increase, with potential positive news anticipated during the mid-year results announcement for fiscal year 2026 [1]

Investment Rating - The investment rating for Geely Automobile is "Buy" [1] Core Views - The report anticipates that Geely Automobile will exceed its sales target of 3.45 million units for 2026, with significant improvements in profitability driven by high-end vehicles and exports [2] - The "Smart Geely 2025" strategy is expected to enhance the company's global competitiveness, leading to higher achievements [9] Sales Performance - In February 2026, Geely's sales reached 206,000 units, a year-on-year increase of 1%. New energy vehicle sales accounted for 117,000 units, with pure electric vehicles at 68,000 units (down 6%) and plug-in hybrids at 50,000 units (up 89%) [9] - For January-February 2026, total sales were 476,000 units, also a 1% year-on-year increase, with new energy vehicle sales at 242,000 units [9] Financial Summary - Total revenue projections for 2026 are RMB 471.165 billion, with a year-on-year growth of 34.5% [8] - Net profit for 2026 is estimated at RMB 23.18 billion, reflecting a growth of 35.5% [8] - The report projects earnings per share (EPS) for 2026 to be RMB 2.14, with a price-to-earnings (PE) ratio of 15 times, leading to a target price of HKD 36.61 [9] Sales Targets - The sales target for 2026 is set at 3.45 million units, representing a 14% increase from 2025, with new energy vehicle sales targeted at 2.22 million units, a 32% increase from the previous year [9]